← Back to home

Growth Hormone Axis

CJC-1295

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog discussed in relation to endogenous growth hormone signaling. It is commonly separated into DAC and non-DAC variants in practice conversations because half-life and exposure patterns differ.

Disclaimer: Not medical advice. Consult a practitioner.

Mechanism overview

CJC-1295 works upstream of growth hormone release by engaging GHRH-related signaling. Rather than supplying growth hormone directly, it is discussed as stimulating the body’s own pituitary release pattern. The DAC-modified version is often described as having a longer duration of action because of albumin binding.

Conditions and use-cases researched for

These are research and discussion areas, not automatic treatment indications.

Evidence notes

CJC-1295 is widely discussed in performance, wellness, and hormone-optimization circles, but those conversations often outpace the rigor of the evidence. Endocrine agents deserve careful framing because changes in GH / IGF-1 signaling can have meaningful downstream effects and are not equivalent to generic wellness supplements.

General literature range note

Published and informal literature commonly refers to microgram-range exposure discussions for CJC-1295, with major differences depending on formulation and study design. No protocol is provided here.

Safety and practical context

Vendor listing for CJC-1295

Interested in being listed as a verified CJC-1295 supplier? Listings start at $29 for basic exposure. Featured suppliers get homepage visibility and category placement.

List my business — $29Featured — $79/mo
Disclaimer: Not medical advice. Consult a practitioner.